The GRPEL2 Knockout SK-HEP-1 Polyclonal Cells are a polyclonal cell population generated by CRISPR/Cas9-mediated gene disruption of the GRPEL2 locus in the SK-HEP-1 human liver adenocarcinoma cell line. This product provides a mixed knockout cell pool with loss-of-function of GRPEL2, enabling functional studies of mitochondrial protein homeostasis. The polyclonal format captures heterogeneous editing outcomes across the cell population, preserving biological variability while ensuring robust target-gene disruption.
The SK-HEP-1 host cell line is an epithelial cell line originally derived from ascites of a male patient with hepatic adenocarcinoma. Widely employed in hepatocellular carcinoma (HCC) research, SK-HEP-1 cells display both epithelial and mesenchymal traits, facilitating investigations into cancer cell plasticity, metastasis, and drug resistance. This established model is well-characterized for metabolic and mitochondrial studies, making it an appropriate background for interrogation of mitochondrial chaperone functions.
GRPEL2 encodes a mitochondrial nucleotide exchange factor that acts as an essential co-chaperone for mtHsp70 (HSPA9), driving ADP release and ATP binding to sustain the mitochondrial Hsp70 chaperone cycle. Functioning within the mitochondrial protein import and folding machinery, GRPEL2 interacts with TIMM44, PAM16, and DNAJC19 to regulate precursor protein translocation and folding. Its expression is regulated by mitochondrial stress signals and key transcriptional regulators such as PGC-1??, NRF1, and TFAM, linking mitochondrial biogenesis to quality control. Disruption of GRPEL2 thus impairs mtHsp70 activity, leading to defective protein import, accumulation of unfolded proteins, and activation of the mitochondrial unfolded protein response (UPRmt).
In the context of SK-HEP-1 liver cancer cells, GRPEL2 knockout is anticipated to perturb mitochondrial proteostasis, triggering metabolic reprogramming and altered stress responses relevant to hepatocellular carcinoma. Loss of GRPEL2 function may compromise oxidative phosphorylation, enhance glycolytic flux, and sensitize cells to mitochondrial stressors, thereby providing a tool to dissect how mitochondrial chaperone dysfunction contributes to tumor maintenance, drug resistance, and cancer cell survival. This model enables examination of crosstalk between mitochondrial health and oncogenic signaling in an epithelial tumor microenvironment.
This GRPEL2 polyclonal knockout model is suited for applications including investigation of mitochondrial protein import defects, analysis of UPRmt activation, and metabolic flux profiling using Seahorse analysis or targeted metabolomics. The cells support western blotting and RT-qPCR for mitochondrial gene expression, co-immunoprecipitation of mtHsp70 complexes, and functional assays examining apoptosis, migration, and drug sensitivity. Researchers studying mitochondrial dysfunction-related diseases, metabolic disorders, or liver cancer biology will find this tool useful for identifying GRPEL2-dependent pathways. For additional information, please contact Ascent Research.
